Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET fusion |
| Therapy | APS03118 |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET fusion | lung non-small cell carcinoma | predicted - sensitive | APS03118 | Phase I | Actionable | In a Phase I trial, treatment with APS03118 demonstrated manageable safety and resulted in an objective response rate of 80% (20/22) and median progression-free survival not reached in treatment-naive non-small cell lung cancer patients harboring RET fusions, an ORR of 55% in patients with prior systemic therapy, and an ORR of 23% in patients with prior selective RET inhibitor treatment without known bypass mutations (J Clin Oncol 44: 16_Suppl, 8617; NCT05653869). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial. | Full reference... |